Johnson & Johnson (J&J, NYSE: JNJ) announced its third‑quarter results for 2025, showing a 5.4 % year‑on‑year (YoY) increase in constant‑currency sales to USD 23.99 billion. The U.S. market grew 6.2 % to USD 13.7 billion, while international markets rose 4.4 % to USD 10.29 billion. Chief Executive Officer Joaquin Duato described the company as entering “a new era of accelerated growth and innovation” thanks to its expanding drug and device portfolio.
Financial Highlights
| Metric | Q3 2025 | YoY Change | Notes |
|---|---|---|---|
| Total Group Sales | USD 23.99 B | +5.4 % | Constant‑currency |
| U.S. Sales | USD 13.70 B | +6.2 % | |
| International Sales | USD 10.29 B | +4.4 % | |
| Full‑Year Guidance | 3.5 %–4.0 % | Raised from 3.2 %–3.7 % | +USD 300 M to USD 93.0 B–93.4 B |
Business Unit Performance
| Unit | Q3 Sales (USD B) | YoY Growth | Comments |
|---|---|---|---|
| Innovative Medicines | 15.56 | +5.3 % | Strong oncology & immunology drivers |
| MedTech | 8.43 | +5.6 % | Sustained device pipeline momentum |
Pharma Unit Highlights
Oncology – +19.2 % to USD 6.53 B
- Darzalex (daratumumab) – +19.9 % to USD 3.67 B
- Carvykti (ciltacabtagene autoleucel) – +81.4 % to USD 524 M
- Erleada (apalutamide) – +15.3 % to USD 936 M
- Rybrevant + Lazcluse combo – USD 198 M, > 2× YoY
- Imbruvica – −10.6 % to USD 695 M
Immunology – −10.6 % to USD 4.17 B
- Tremfya (guselkumab) – +40.1 % to USD 1.42 B
- Simponi/Simponi Aria – +31.5 % to USD 687 M
- Stelara (ustekinumab) – −42 % to USD 1.57 B (biosimilar pressure)
Excluding Stelara, overall pharma grew 16 % YoY.
Neuroscience – +14.6 % to USD 2.02 B
- Spravato (esketamine) – +60.8 % to USD 459 M
Pipeline Developments
- Icotrokinra – First‑in‑class oral IL‑23 receptor blocker; Phase IIb ANTHEM‑UC study achieved 63.5 % clinical response at 400 mg vs. 27 % placebo (p < 0.001).
Potential oral alternative to injected biologics for ulcerative colitis. - NDA Filing – July 2025 for moderate‑to‑severe plaque psoriasis; additional indications in Crohn’s disease and psoriatic arthritis under development.
Orthopedics Spin‑Off
Johnson & Johnson announced plans to spin off its orthopedics unit into a standalone company, DePuy Synthes. The transaction, subject to board and regulatory approval, is expected to take 18–24 months. DePuy Synthes will generate USD 9.2 B in annual revenue, positioning it as the world’s largest, most comprehensive orthopedics‑focused firm.
- Leadership – Namal Nawana named president; former chairman of Sapphiros and CEO of Smith & Nephew Plc.
- Strategy – Duarto emphasized that a stand‑alone entity can “drive growth, innovation, and better margins” in a lower‑growth orthopedics market.
Forward‑Looking Statements
This release contains forward‑looking statements regarding future performance, product development, and regulatory approvals. Actual results may differ materially.-Fineline Info & Tech
